Azenta Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Azenta şu anda temettü ödemiyor.

Anahtar bilgiler

Temettü verimi

26.9%

Geri Alım Getirisi

Toplam Hissedar Getirisi	26.9%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	US$0.400
Ödeme oranı	0%

Son temettü ve geri alım güncellemeleri

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 0HQ1 şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: 0HQ1 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Azenta Piyasaya Karşı Temettü Getirisi

0HQ1 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (0HQ1)	0%
Pazarın Alt %25'i (GB)	2.1%
Pazarın En İyi %25'i (GB)	5.8%
Sektör Ortalaması (Life Sciences)	0.7%
Analist tahmini (0HQ1) (3 yıla kadar)	0%

Önemli Temettü: 0HQ1 şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, 0HQ1 şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: 0HQ1 UK piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: 0HQ1 herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Azenta Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Upcoming dividend of US$0.10 per share

Upcoming dividend of US$0.10 per share

Recent updates

Azenta, Inc.(NasdaqGS:AZTA) dropped from S&P 400 Health Care (Sector)

Independent Director recently bought US$495k worth of stock

Full year 2024 earnings released: US$3.09 loss per share (vs US$0.19 loss in FY 2023)

Azenta, Inc. Announces Chief Financial Officer Changes

Azenta, Inc. to Report Q4, 2024 Results on Nov 12, 2024

Azenta, Inc Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test

Azenta, Inc. Announces Management Changes

Forecast to breakeven in 2026

No longer forecast to breakeven

New minor risk - Share price stability

Azenta, Inc. to Report Q3, 2024 Results on Aug 06, 2024

Azenta, Inc. Provides Earnings Guidance for the Full Fiscal Year 2024

Second quarter 2024 earnings released: US$2.47 loss per share (vs US$0.029 loss in 2Q 2023)

Stephen Schwartz to Retire as CEO of Azenta, Inc

Azenta, Inc. to Report Q2, 2024 Results on May 08, 2024

Now 21% overvalued

High number of new directors

Now 20% overvalued

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.15 loss in 1Q 2023)

High number of new directors

Azenta, Inc. Announces the Launch of the BioArc Ultra

Azenta, Inc. to Report Q1, 2024 Results on Feb 07, 2024

Azenta, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Ellen M. Zane Decides Not to Stand for Election to the Board of Directors of Azenta, Inc

Azenta, Inc., Annual General Meeting, Jan 30, 2024

Azenta, Inc. Provides Earnings Guidance for the Full Year Fiscal 2024

Full year 2023 earnings released: US$0.19 loss per share (vs US$0.15 loss in FY 2022)

Azenta, Inc. to Report Q4, 2023 Results on Nov 13, 2023

Politan Capital Provides Information to the Shareholders

Azenta, Inc. Announces Chief Financial Officer Changes, Effective October 16, 2023

Azenta, Inc. Announces Executive Vice President Changes, Effective October 16, 2023

Politan Capital Management Engages in Discussions with Azenta

Politan Capital Management Engages in Discussions with Azenta

New minor risk - Insider selling

Insider recently sold US$407k worth of stock

Third quarter 2023 earnings released: US$0.039 loss per share (vs US$0.094 loss in 3Q 2022)

Azenta, Inc. Revises Revenue Guidance for the Full Year of 2023

Azenta, Inc. to Report Q3, 2023 Results on Aug 08, 2023

Forecast breakeven date pushed back to 2025

Second quarter 2023 earnings released: US$0.029 loss per share (vs US$0.024 loss in 2Q 2022)

Azenta, Inc. Provides Earnings Guidance for the Third Quarter of Fiscal Year 2023

Azenta, Inc. to Report Q2, 2023 Results on May 09, 2023

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.038 profit in 1Q 2022)

Azenta, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2023

Azenta, Inc. to Report Q1, 2023 Results on Feb 08, 2023

Azenta, Inc. (NasdaqGS:AZTA) acquired Ziath Ltd.

Azenta, Inc. Announces Election of Directors

Azenta, Inc., Annual General Meeting, Jan 31, 2023

Full year 2022 earnings released: US$0.15 loss per share (vs US$0.39 loss in FY 2021)

Azenta Announces Board Resignations

Azenta, Inc. to Report Q4, 2022 Results on Nov 14, 2022

Azenta, Inc. Announces Matthew McManus Would No Longer Serve as the Companys Chief Operating Officer Effective as of October 14, 2022

Azenta, Inc. (NasdaqGS:AZTA) acquired B Medical Systems S.à R.L. from Navis Capital Partners.

Executive VP & COO recently bought US$502k worth of stock

Third quarter 2022 earnings released: US$0.094 loss per share (vs US$0.53 profit in 3Q 2021)

Azenta, Inc. Provides Earnings Guidance for the Fourth Quarter Fiscal 2022

Azenta, Inc. (NasdaqGS:AZTA) entered into an agreement to acquire B Medical Systems S.à R.L. for approximately €460 million.

Azenta, Inc. Provides Earnings Guidance for the Third Fiscal Quarter Ended June 30, 2022

Azenta, Inc.(NasdaqGS:AZTA) dropped from Russell 3000E Growth Index

Azenta, Inc. announced delayed 10-Q filing

Second quarter 2022 earnings released: US$0.024 loss per share (vs US$0.32 profit in 2Q 2021)

Azenta, Inc. Provides Revenue Guidance for the Third Quarter of 2022

Azenta, Inc. to Report Q2, 2022 Results on May 03, 2022

Forecast breakeven date moved forward to 2022

Azenta, Inc. Provides Earnings Guidance for the Second Quarter Fiscal Year 2022

Azenta, Inc. Announces Executive Changes

Forecast breakeven date pushed back to 2023

Azenta, Inc.(NasdaqGS:AZTA) dropped from NASDAQ Composite Index

Upcoming dividend of US$0.10 per share

Independent Director recently sold US$323k worth of stock

Full year 2021 earnings released: US$0.39 loss per share (vs US$0.88 profit in FY 2020)

Insufficient new directors